ribavirin has been researched along with Adverse Drug Event in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (10.61) | 29.6817 |
| 2010's | 57 (86.36) | 24.3611 |
| 2020's | 2 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, S; Chen, Z; Liang, A; Qiu, R; Shang, H; Sun, Y; Wang, P; Zhang, X; Zhao, C; Zheng, R | 1 |
| El-Marakby, MG; Sabri, NA; Solayman, MH | 1 |
| Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H | 1 |
| Ardèvol, M; Carrión, JA; Gallego, A; González-Colominas, E; Lens, S; Londoño, MC; López, D; Mariño, Z; Mojal, S; Morillas, RM; Pagès, N; Solà, R; Torras, X | 1 |
| Badshah, C; Barr, E; Brown, A; Durkan, C; Foster, GR; Haber, B; Hézode, C; Lahser, F; Roberts, SK; Robertson, M; Wahl, J; Zekry, A; Zhang, B; Zuckerman, E | 1 |
| Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Amador, C; Carmena, J; Flores, J; Galindo, MJ; García-Deltoro, M; Masiá, M; Mínguez, C; Montero, M; Ortega, E; Reus, S | 1 |
| Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C | 1 |
| Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH | 1 |
| Abdel-Razek, W; Brainard, DM; Doss, W; Elbasiony, M; Elsharkawy, A; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Kersey, K; Lu, S; Massetto, B; McHutchison, JG; Osinusi, A; Shiha, G; Soliman, R; Waked, I; Zakareya, T | 1 |
| Béguelin, C; Bernasconi, E; Böni, J; Braun, DL; Conen, A; Delaloye, J; Fehr, JS; Flepp, M; Günthard, HF; Hampel, B; Kouyos, R; Künzler-Heule, P; Nguyen, H; Nicca, D; Rauch, A; Rougemont, M; Schmid, P; Shah, C; Stöckle, M | 1 |
| Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM | 1 |
| Eom, JS; Joo, YS; Jung, Y; Ko, JH; Lee, JS; Park, SY; Peck, KR; Shi, H; Son, JS; Woo, HJ | 1 |
| Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E | 1 |
| Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K | 1 |
| Deng, H; Fan, X; Han, Q; Li, N; Liu, Z; Wang, X; Wang, Y; Zhang, K; Zhang, X | 1 |
| Anzai, K; Eguchi, Y; Hirai, M; Isoda, H; Iwane, S; Izumi, N; Kawaguchi, Y; Kimura, S; Kurose, K; Mizuta, T; Nakashita, S; Oeda, S; Ozaki, I; Takahashi, H | 1 |
| Andreoletti, M; Borroni, G; Cazzaniga, M; Ceriani, R; Guerzoni, P; Omazzi, B; Pich, MG; Prada, A; Salerno, F; Spinzi, G; Terreni, N | 1 |
| Backus, LI; Belperio, PS; Cheung, RC; Hwang, EW; Mole, LA; Thomas, IC | 1 |
| Cooper, C; Fainboim, H; Greaves, W; Howe, AY; Mak, C; Mallolas, J; Pol, S; Rivero, A; Sklar, P; Slim, J; Sulkowski, M; Thompson, S; Wahl, J; Wenning, L | 1 |
| Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL | 1 |
| Akuta, N; Hara, T; Hosaka, T; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Aston, CE; Bader, T; Dunnam, M; Fazili, J; Frost, B; Gonterman, A; Hughes, LD; Madhoun, M | 1 |
| Bon, D; Cai, SY; Haagmans, B; Herrmann, E; Kottilil, S; Lee, YJ; Lempicki, R; Masur, H; Nelson, A; Osinusi, A; Polis, M; Poonia, S; Shivakumar, B; Sneller, M; Wood, B | 1 |
| Ahadi-Barzoki, M; Dashti-Khavidaki, S; Karimzadeh, I; Khalili, H; Nasiri-Toosi, M; Ravi, S | 1 |
| Ridruejo, E | 1 |
| Amiri, M; Bailly, F; Funingana, G; Gonçalves, F; Hartig-Lavie, K; Maynard, M; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Delang, L; Neyts, J; Verpaalen, B | 1 |
| Aimitsu, S; Aisaka, Y; Chayama, K; Hayes, CN; Kawakami, H; Kawakami, Y; Kira, S; Kitamoto, M; Kohno, H; Moriya, T; Nakanishi, T; Nonaka, M; Takahashi, S; Tsuji, K; Yamashina, K; Yokoyama, S | 1 |
| Berg, CP; Egetemeyr, DP; Franz, C; Janke-Maier, P; Lauer, UM; Malek, NP; Werner, CR | 1 |
| Dybowska, D; Halota, W; Kozielewicz, D | 1 |
| Abrignani, S; Almasio, P; Ascione, A; Bonino, F; Brunetto, MR; Colombatto, P; Houghton, M; Maina, AM; Mondelli, M; Muratori, L; Pinzello, G; Rappuoli, R; Romagnoli, V; Rosa, D; Rumi, MG | 1 |
| Dixit, V; Fabrizi, F; Martin, P; Messa, P | 1 |
| Climente-Martí, M; Gómez-Álvarez, S; Guglieri-López, B; Ventura-Cerdá, JM | 1 |
| Brainard, D; Dvory-Sobol, H; Gao, B; Garrison, KL; Genda, T; Hino, K; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, S; McHutchison, JG; Mizokami, M; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Nishiguchi, S; Omata, M; Omote, M; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Aichelburg, MC; Grabmeier-Pfistershammer, K; Lang, G; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Beumont-Mauviel, M; De La Rosa, G; Forns, X; Fried, MW; Fu, M; Jacobson, IM; Jessner, W; Kalmeijer, R; Lenz, O; Manns, MP; Ouwerkerk-Mahadevan, S; Peeters, M; Poordad, F; Scott, JA; Sinha, R; Zeuzem, S | 1 |
| Alberti, A; Brass, C; Buti, M; Calistru, P; Chuang, WL; Davis, GL; Flisiak, R; Goeser, T; Horban, A; Kao, JH; Mazzella, G; Orsenigo, R; Pol, S; Rasenack, J; Streinu-Cercel, A; Tabak, F | 1 |
| Arbuckle, R; Beumont, M; Brohan, E; Fu, M; Gilles, L; Jessner, W; Panter, C; Scott, J | 1 |
| Cohen, S; Cooney, E; DeMicco, M; Ghalib, R; Hanson, J; Hughes, E; Lawitz, E; Martorell, C; Ravendhran, N; Rustgi, V; Tatum, H; Thuluvath, PJ; Treitel, M; Zamparo, J; Zhao, J | 1 |
| Araki, Y; Ikeda, F; Iwasaki, Y; Kobashi, H; Miyake, Y; Okamoto, R; Takaki, A; Taniguchi, H; Yamamoto, K | 1 |
| Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Bhagani, S; Collado, A; de Los Santos-Gil, I; Delgado, M; Fehr, J; Haberl, A; López-Cortés, LF; Lutz, T; Mandorfer, M; Márquez, M; Mauss, S; Munteanu, DI; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S; Stoeckle, M | 1 |
| Araki, Y; Hashimoto, N; Ishii, Y; Iwasaki, Y; Okamoto, R; Yamamoto, K | 1 |
| Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C | 1 |
| Durant, J; Girard, PM; González-García, J; Grinsztejn, B; Horban, A; Janssen, K; Lathouwers, E; Montes, ML; Nelson, M; Ortega-Gonzalez, E; Ouwerkerk-Mahadevan, S; Rivero, A; Sasadeusz, J; Witek, J; Zakharova, N | 1 |
| Ahn, SH; Brainard, DM; Byun, KS; Han, KH; Han, L; Han, SY; Heo, J; Jeong, SH; Kim, JH; Kim, YJ; Kim, YS; Knox, SJ; Lee, KS; Lee, YJ; Lim, YS; Mathias, A; Mo, H; Paik, SW; Tak, WY; Yang, JC; Yim, HJ; Yoon, SK | 1 |
| Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E | 1 |
| Acharya, SK; Chowdhury, A; Doehle, B; Duseja, A; Jiang, D; Kanwar, B; Kapoor, D; Kersey, K; Koshy, A; Madan, K; Mehta, R; Nijhawan, S; Pawan, R; Prasad, M; Sarin, S; Shah, SR; Shukla, A; Sood, A; Subramanian, M; Sud, R; Svarovskaia, E | 1 |
| Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A | 1 |
| Akremi, R; Allegre, T; Antonini, T; Aumaitre, H; Batisse, D; Bennai, Y; Billaud, E; Chas, J; Dabis, F; De Ledinghen, V; De Truchis, P; Dhiver, C; Dominguez, S; Fedchuk, L; Filipovics, A; Fontaine, H; Harent, S; Lacombe, K; Lafeuillade, A; Leroy, V; Metivier, S; Miailhes, P; Pageaux, GP; Perre, P; Rosenthal, E; Salmon Ceron, D; Sogni, P; Valantin, MA; Zhao, Y | 1 |
| Malinin, OV; Platonov, AE | 1 |
| Bassetti, M; Beltrame, A; Dentone, C; Di Biagio, A; Lindstrom, V; Mazzarello, G; Ratto, S; Righi, E; Viscoli, C | 1 |
| Deutch, M; Dourakis, S; Ioannidou, P; Karafoulidou, A; Katsarou, O; Kouraba, A; Nomikou, E; Terpos, E; Theodosiades, G; Tsevrenis, B | 1 |
| Boudreau, EF; Byrne, WR; Chung, KN; Cosgriff, T; Erlichman, MS; Gibbs, PH; Huggins, JW; Kim, KY; Kim, TT; Pittman, P; Rezvani, DF; Rusnak, JM | 1 |
| Bishop, R; Cortez, KJ; Kottilil, S; Masur, H; McLaughlin, M; Murphy, A; Osinusi, A; Polis, MA; Proschan, M; Rasimas, JJ; Rosenstein, D | 1 |
| Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML | 1 |
| Almeida, JR; França, AV; Júnior, LJ; Nogueira, JB; Quintans, Jde S; Sena, LC | 1 |
| Cooper, CL; Druyts, E; Kanters, S; Mills, EJ; Thorlund, K; Wu, P; Yaya, S | 1 |
| Fukuoka, M; Hata, T; Kudo, M; Kuwano, H; Kuwao, H; Moriyama, K; Naitoh, S; Nomura, M; Tohda, Y | 1 |
| Berg, T; Hadziyannis, SJ; Jorga, K; Marcellin, P; Puoti, C; Snoeck, E; Swain, MG; Zarski, JP; Zeuzem, S | 1 |
| Carson, S; Chan, BK; Chou, R | 1 |
8 review(s) available for ribavirin and Adverse Drug Event
| Article | Year |
|---|---|
Clinical features of adverse events associated with Xiyanping-Ribavirin combination: A systematic review.
Topics: Animals; Child; Child, Preschool; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Foot-and-Mouth Disease; Humans; Infant; Infant, Newborn; Pneumonia, Viral; Randomized Controlled Trials as Topic; Ribavirin | 2022 |
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response | 2023 |
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2017 |
Safety of direct-acting antivirals in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Protease Inhibitors; Ribavirin | 2014 |
Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.
Topics: Antiviral Agents; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Poland; Practice Guidelines as Topic; Proline; Protease Inhibitors; Ribavirin | 2013 |
Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Renal Dialysis; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials.
Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Treatment Outcome; Viral Load | 2008 |
23 trial(s) available for ribavirin and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Pancytopenia; Ribavirin; Sofosbuvir; Thrombocytopenia; Treatment Outcome | 2018 |
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2019 |
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Placebos; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Fatty Acids, Monounsaturated; Fluvastatin; Genotype; Hepacivirus; Hepatitis C; Humans; Indoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2013 |
Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin; Treatment Outcome; Viral Load; Vitamin D; Vitamins | 2014 |
HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial.
Topics: Adjuvants, Immunologic; Antibodies, Neutralizing; Antiviral Agents; CD4-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Injections, Intramuscular; Interferon-alpha; Polyethylene Glycols; Polysorbates; Recombinant Proteins; Ribavirin; RNA, Viral; Squalene; Treatment Outcome; Vaccines, Synthetic; Viral Hepatitis Vaccines; Viral Load | 2014 |
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2014 |
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.
Topics: Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Salvage Therapy; Treatment Outcome; Viral Load; Young Adult | 2015 |
Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST-1, QUEST-2 an
Topics: Adolescent; Adult; Aged; Anemia; Depression; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Male; Middle Aged; Placebos; Ribavirin; Simeprevir; Treatment Outcome; Viral Load; Young Adult | 2015 |
A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
Topics: Adult; Antiviral Agents; Benzazepines; Double-Blind Method; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon-alpha; Male; Middle Aged; Placebos; Ribavirin; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Young Adult | 2015 |
Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load | 2015 |
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2015 |
Randomized trial of low-dose peginterferon α-2b plus low and escalating doses of ribavirin in older patients with chronic hepatitis C with high viral load genotype 1.
Topics: Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Treatment Outcome; Viral Load | 2015 |
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2015 |
Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Young Adult | 2016 |
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2016 |
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2017 |
Insufficient efficacy and safety of intravenous ribavirin in treatment of haemorrhagic fever with renal syndrome caused by Puumala virus.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhagic Fever with Renal Syndrome; Humans; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Puumala virus; Ribavirin; Russia; Treatment Outcome; Viral Load; Young Adult | 2017 |
Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Blood Coagulation Disorders, Inherited; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2008 |
HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
Topics: Adult; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Eye Diseases; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2010 |
35 other study(ies) available for ribavirin and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; Retrospective Studies; Ribavirin; Spain; Treatment Outcome; Young Adult | 2018 |
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Carbamates; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
Topics: Adult; Aged; Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Imidazoles; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Quinoxalines; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
Topics: Adult; Aged; Antiviral Agents; Coronavirus Infections; Drug-Related Side Effects and Adverse Reactions; Female; Health Personnel; Humans; Incidence; Lopinavir; Male; Post-Exposure Prophylaxis; Retrospective Studies; Ribavirin; Ritonavir; Young Adult | 2019 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
Topics: Adult; Antiviral Agents; Asian People; China; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.
Topics: Antiviral Agents; Automation, Laboratory; Clinical Laboratory Techniques; Drug-Related Side Effects and Adverse Reactions; Genetic Testing; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferons; Interleukins; Polymorphism, Single Nucleotide; Pyrophosphatases; Ribavirin | 2013 |
Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Ribavirin; Risk Factors | 2013 |
Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.
Topics: Aged; Anemia; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Treatment Outcome; Veterans; Viral Load | 2013 |
High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Interferon-alpha; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Severity of Illness Index; United States; Withholding Treatment | 2013 |
A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Japan; Male; Oligopeptides; Pilot Projects; Ribavirin; Treatment Outcome | 2013 |
Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.
Topics: Adult; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Profiling; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Treatment Outcome | 2014 |
Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Ribavirin; Young Adult | 2014 |
Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score.
Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; End Stage Liver Disease; Female; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Kidney; Kidney Function Tests; Male; Middle Aged; Oligopeptides; Proline; Prospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome; Viral Load | 2014 |
Are statins a viable option for the treatment of infections with the hepatitis C virus?
Topics: Anticholesteremic Agents; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Ribavirin; Treatment Outcome; Virus Replication | 2014 |
Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Humans; Interferons; Male; Middle Aged; Oligopeptides; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2014 |
[Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment].
Topics: Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Retrospective Studies; Ribavirin; Time Factors | 2015 |
Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study.
Topics: Adult; Antiviral Agents; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.
Topics: Anemia; Antiviral Agents; Bilirubin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Exanthema; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Neutropenia; Prevalence; Pruritus; Ribavirin; Simeprevir | 2015 |
Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.
Topics: Adult; Coinfection; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Proline; Ribavirin; Treatment Outcome | 2015 |
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Italy; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Demography; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome | 2008 |
Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea.
Topics: Adult; Anemia, Hemolytic; Antiviral Agents; Bradycardia; Cohort Studies; Creatinine; Drug-Related Side Effects and Adverse Reactions; Female; Hantaan virus; Hemorrhagic Fever with Renal Syndrome; Humans; Infusions, Intravenous; Korea; Male; Middle Aged; Ribavirin; Young Adult | 2009 |
Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2010 |
Side effects of the therapy with peginterferon and ribavirin in chronic hepatitis C: a small audit.
Topics: Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Retrospective Studies; Ribavirin; Young Adult | 2012 |
Studies on the variation in clinical laboratory data and safety evaluation of pharmaceuticals.
Topics: Antiviral Agents; Clinical Laboratory Information Systems; Clinical Laboratory Techniques; Clinical Trials as Topic; Data Interpretation, Statistical; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Selection; Pharmaceutical Preparations; Reference Values; Ribavirin; Sensitivity and Specificity | 2005 |
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin.
Topics: Alanine Transaminase; Anemia; Computer Simulation; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Models, Theoretical; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome | 2008 |